Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development stage company, is focused on safer, more effective, less invasive and more economical oncology and dermatology therapies. Currently, the company is conducting Phase 2 clinical trials of their proprietary drugs designed to treat psoriasis, metastatic melanoma, and atopic dermatitis. Provectus has developed multiple intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For further information, visit the Company’s web site at www.pvct.com.
- 17 years ago
QualityStocks
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT)
Tags Rodman & Renshaw
Related Post
-
Blockchain Futurist Conference Florida 2025 Kicks Off in Just 2 Weeks, Featuring Iggy Azalea, Tristan Thompson, and Leaders in Web3 & AI
The Blockchain Futurist Conference Florida 2025, now in its eighth edition and first-ever U.S. event,…
-
Fairchild Gold Corp. (TSX.V: FAIR): LOI for Nevada Expansion Strengthens Position Amid Record Gold Outlooks
Memorandum of Understanding signed to acquire the Golden Arrow Project in Nevada’s Walker Lane Belt…
-
BluSky AI Inc. (BSAI) Poised to Reshape AI Infrastructure Deployment While Industry Demand Surges
Google's substantial AI investment in innovation underscores the explosive demand for computing power across the…